Trial Profile
An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jul 2019
Price :
$35
*
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Adverse reactions; Registrational
- Acronyms KODIAC-08
- Sponsors AstraZeneca
- 16 May 2015 Results published in Digestive Disease Week, according to a Daiichi Sankyo media release.
- 16 May 2015 Results published in a Daiichi Sankyo media release.
- 16 Sep 2014 Naloxegol was approved in the US for the treatment of opioid-induced constipation, based on data from this and other trials in the phase III KODIAC programme.